Answers are grounded in this paper and cite their sources.
Analysis shows coverage-promoting policies affect buprenorphine treatment initiation and discontinuation during Medicaid changes, indicating varying effectiveness.
Objectives: We examined associations between coverage-promoting policies and changes in initiation and discontinuation of buprenorphine treatment during Medicaid unwinding. Methods: We conducted a retrospective analysis of national retail pharmacy data (2021–2023) to examine the association between 4 separate coverage-promoting policies and the number of initiations and discontinuations of buprenorphine treatment episodes in the 6 months after unwinding began. Statistical significance was assessed using 2-sample t tests. Results: Following up with enrollees nonresponsive to renewal requests and improving ex parte renewal rates were associated with smaller decreases in initiations (−1.4 percentage point difference [pp] [95% CI: −1.5 to −1.4] and −1.5 pp [95% CI: −1.5 to −1.5], respectively) and smaller increases in discontinuations (0.6 pp [95% CI: 0.5–0.7] and 0.6 pp [95% CI: 0.6–0.7], respectively). Following up on returned mail and mostly automated renewal processing had mixed effects. Following up on returned mail was associated with a larger decrease in initiations (1.1 pp [95% CI: 1.0–1.2]) but a smaller increase in discontinuations (1.1 pp [95% CI: 1.0–1.2]); automated renewal processing was associated with a smaller decrease in initiations (−1.6 pp [95% CI: −1.6 to −1.6]) but a larger increase in discontinuations (−2.5 pp [95% CI: −2.6 to −2.5]). Conclusions: Some coverage-promoting policies were associated with smaller disruptions in buprenorphine treatment during Medicaid unwinding; potential protective effects varied by policy type.
No takes yet. Share an insight, caveat, or question.
Landis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: